Mucositis oral en el paciente con terapia antineoplásica
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
La mucositis oral es una de las complicaciones más frecuentes y sintomáticas de la terapia antineoplásica y se asocia con un aumento significativo en la morbilidad, dolor, limitación funcional, deterioro en la calidad de vida y costos globales de la atención médica. La incidencia de inflamación de la mucosa (mucositis) en pacientes con cáncer de cabeza y cuello sometidos a radioterapia puede ser tan alta como un 100%; aquellos que reciben quimioterapia presentan mucositis hasta en un 40-70%, de acuerdo con el esquema asignado. Múltiples estrategias han sido estudiadas tanto para la prevención como para el manejo de la mucositis oral, pero los resultados no son consistentes y muchas de las intervenciones actuales son utilizadas de manera empírica, sin tener evidencia científica que soporte la continuidad o no de su uso.
Citas
Köstler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin. 2001; 51(5):290-315.
Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapyinduced oral and gastrointestinal mucositis. Cancer. 2004; 100(9 Suppl): 2026-2046.
Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist. 1998;3 (6):446-451
Treister N, Sonis S. Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg. 2007; 15(2):123-129.
Sieracki RL, Voelz LM, Johannik TM, Kopaczewski DM, Hubert K. Development and implementation of an oral care protocol for patients with cancer. Clin J Oncol Nurs. 2009;13(6):718-722
Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy: clinical and economic outcomes of chemotherapyinduced mucositis. Cancer. 2003; 98(7):1531-1539.
Borbasi S, Cameron K, Quested B, Olver I, To B, Evans D. More than a sore mouth: patients’ experience of oral mucositis. Oncol Nurs Forum. 2002; 29(7):1051- 1057.
Lalla RV, Peterson DE. Treatment of mucositis, including new medications. Cancer J. 2006;12(5):348-354
Sadler GR, Oberle-Edwards L, Farooqi A, Hryniuk WM. Oral sequelae of chemotherapy: an important teaching opportunity for oncology health care providers and their patients. Support Care Cancer. 2000; 8(3):209-214.
Sadler GR, Stoudt A, Fullerton JT, Oberle-Edwards LK, Nguyen Q, Epstein JB. Managing the oral sequelae of cancer therapy. Medsurg Nurs. 2003; 12(1):28-36.
Sonis ST. Pathobiology of oral mucositis:novel insights and opportunities. J Support Oncol. 2007;5(9 Supp 4):3-11
Eilers J, Epstein J. Assessment and measurement of oral mucositis. Semin Oncol Nurs. 2004; 20(1): 22–29.
Jones JA, Avritscher EBC, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatmentassociated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006; 14(6):505-515.
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber – Durlacher JE, et al. Updated clinical practice for the prevention and treatment of mucositis. Cancer. 2007;109 (5):820-831
Avritscher EB, Cooksley CD, Elting LS. Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis. Semin Oncol Nurs. 2004; 20(1):3-10
Vissink A, Jansma J, Spijkervet FK, Burlage FR, Copes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003;14(3):199-212
Epstein JB, Freilich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol. 1993; 76(2):169-174
Vissink A, Burlage FR, Spijkervet FK, Jansma J, Copes RP. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med. 2003; 14(3):213-225
Eilers J, Million R. Prevention and management of oral mucositis in patients with cancer. Semin Oncol Nurs. 2007; 23(3):201-212.
Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4(4):277-284
Coulson S. Mouth care in children with cancer. Paediatr Nurs. 2007; 19(4):18.
Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004; 22(7):1268-1275.
Zlotolow IM, Berger AM. Oral manifestations and complications of cancer therapy. In: Berger AM, Portenoy RK, Weissman DE, editores. Principles and practice of palliative care and supportive oncology. 2. ed. Philadelphia:Lippincott Williams Wilkins; 2002. p. 282-298.
Sonis ST. A biologic approach to mucositis. J Support Oncol. 2004;2(1):21-36
Jaroneski LA. The importance of assessment rating scales for chemotherapy-induced oral mucositis. Oncol Nurs Forum. 2006; 33(6):1085-1090.
Wong PC, Dodd MJ, Miaskowski C, Paul SM, Bank KA, Shiba GH, et al. Mucositis pain induced by radiation therapy: prevalence, severity, and use of self-care behaviors. J Pain Symptom Manage. 2006; 32(1):27- 37.
Redding SW. Cancer therapy-related oral mucositis. J Dent Educ. 2005;69(8):919-929
Dodd M, Larson P, Dibble S, Miaskowski C, Greenspan D, Macphail L, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of mucositis in patients receiving chemotherapy. Oncol Nurs Forum. 1996; 23(6):921–927.
Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM, et al. Oral glutamine to alleviate radiation induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys. 2000; 46(3):535-539
Jham BC, Teixeira IV, Aboud CG, Carvalho Al, Coelho MM, Freire AR. A randomized phase III prospective trial of bethanecol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer. Oral Oncol. 2007;43(2):137-142
Jham BC, Chen H, Carvalho AL, Freire AR. A randomized phase III prospective trial of bethanecol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. J Oral Sc. 2009; 51(4):565-572.
Miller M, Kearney N. Oral care for patients with cancer: a review of the literature. Cancer Nurs. 2001; 24(4):241-254
Mead GM. Management of oral mucositis associated with cancer chemotherapy. Lancet. 2002; 359(9309):815- 816
Barasch A, Elad S, Altman A, Damato K, Epstein J. Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer. 2006;14(6):528- 532
Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C. Putting Evidence Into Practice: Evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs. 2008; 12(1):141–152.
Silverman S. Diagnosis and management of oral mucositis. J Support Oncol. 2007; 5(2 Supl 1):13–21.
Kin-fong Cheng K, Tsui Yuen JK. A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer. Cancer Nurs. 2006; 29(5):423-430.
Potting CMJ, Uitterhoeve R, Scholte Op Reimer W, Van Achterberg T. The effectiveness of commonly used mouthwashes for the prevention of chemotherapyinduced oral mucositis: a systematic review. Eur J Cancer Care (Engl). 2006; 15(5):431-439.
Büntzel J, Glatzel M, Kuttner K, Weinaug R, Fröhlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol. 2002;12(Supp 1):4-13
Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Support Care Cancer. 2006; 14(2):137-146.
Caribé-Gomes F, Chimenos-Küstner E, López-López J, Finestres-Zubeldia F, Guix-Melcior B. Dental management of the complications of radio and chemotherapy in oral cancer. Med Oral. 2003;8(3):178- 187
McGuire DB. Barriers and strategies in implementation of oral care standards for cancer patients. Support Care Cancer. 2003; 11(7):435-441.
McGuire DB, Correa ME, Johnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer. 2006; 14(6):541-547.
Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007; 4:CD000978.
Dodd MJ, Miaskowski C, Greenspan D, MacPhail L, Shih AS, Shiba G, et al. Radiation-induced mucositis: A randomized clinical trial of micronized sucralfate versus salt and soda mouthwashes. Cancer Invest. 2003; 21(1):21–33
Dodd MJ, Dibble SL, Miaskowski C, MacPhail L, Greenspan D, Paul SM, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000:90(1), 39–47.
Hogan R. Implementation of an oral care protocol and its effects on oral mucositis. J Pediatr Oncol Nurs. 2009; 26(3):125- 135
Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007; 2:CD001973.
Buchsel PC. Gelclair® Oral Gel. Clin J Oncol Nurs 2003; 7(1):109-110.
Barber C, Powell R, Ellis A, Hewett J. Comparing pain control and ability to eat and drink with Standard therapy vs Gelclair: a preliminary, double centre, randomised controlled trial on patients with radiotherapy-induced oral mucositis. Support Care Cancer. 2007; 15(4):427- 440.
Smith T. Gelclair: managing the symptoms of oral mucositis. Hosp Med. 2001; 62(10):623-626.
Buchsel PC. Polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair): a bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions. Expert Opin Drug Metab Toxicol. 2008;4(11):1449-1454